Rocket Pharmaceuticals, Inc. 9IP1.F Stock
Rocket Pharmaceuticals, Inc. Price Chart
Rocket Pharmaceuticals, Inc. 9IP1.F Financial and Trading Overview
Rocket Pharmaceuticals, Inc. stock price | 20.42 EUR |
Previous Close | 13.8 EUR |
Open | 14.49 EUR |
Bid | 14.64 EUR x 0 |
Ask | 14.69 EUR x 0 |
Day's Range | 14.49 - 14.75 EUR |
52 Week Range | 12.28 - 21.66 EUR |
Volume | 100 EUR |
Avg. Volume | 14 EUR |
Market Cap | 1.19B EUR |
Beta (5Y Monthly) | 1.1531 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.62 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 69.78 EUR |
9IP1.F Valuation Measures
Enterprise Value | 847.72M EUR |
Trailing P/E | N/A |
Forward P/E | -5.7597656 |
PEG Ratio (5 yr expected) | -1.39 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.9460537 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -3.343 |
Trading Information
Rocket Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.1531 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 21.66 EUR |
52 Week Low | 12.28 EUR |
50-Day Moving Average | 17.38 EUR |
200-Day Moving Average | 17.85 EUR |
9IP1.F Share Statistics
Avg. Volume (3 month) | 14 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 80.53M |
Float | 56.88M |
Short Ratio | N/A |
% Held by Insiders | 3.75% |
% Held by Institutions | 100.17% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -36.091% |
Return on Equity (ttm) | -62.86% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -253559008 EUR |
Net Income Avi to Common (ttm) | -248515008 EUR |
Diluted EPS (ttm) | -2.87 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 307.04M EUR |
Total Cash Per Share (mrq) | 3.81 EUR |
Total Debt (mrq) | 25.39M EUR |
Total Debt/Equity (mrq) | 6.3 EUR |
Current Ratio (mrq) | 9.086 |
Book Value Per Share (mrq) | 5.005 |
Cash Flow Statement
Operating Cash Flow (ttm) | -208308992 EUR |
Levered Free Cash Flow (ttm) | -120857248 EUR |
Profile of Rocket Pharmaceuticals, Inc.
Country | Germany |
State | NJ |
City | Cranbury |
Address | 9 Cedarbrook Drive |
ZIP | 08512 |
Phone | 609 659 8001 |
Website | https://rocketpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 240 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.
Q&A For Rocket Pharmaceuticals, Inc. Stock
What is a current 9IP1.F stock price?
Rocket Pharmaceuticals, Inc. 9IP1.F stock price today per share is 20.42 EUR.
How to purchase Rocket Pharmaceuticals, Inc. stock?
You can buy 9IP1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rocket Pharmaceuticals, Inc.?
The stock symbol or ticker of Rocket Pharmaceuticals, Inc. is 9IP1.F.
Which industry does the Rocket Pharmaceuticals, Inc. company belong to?
The Rocket Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Rocket Pharmaceuticals, Inc. have in circulation?
The max supply of Rocket Pharmaceuticals, Inc. shares is 90.78M.
What is Rocket Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Rocket Pharmaceuticals, Inc. PE Ratio is now.
What was Rocket Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Rocket Pharmaceuticals, Inc. EPS is -2.62 EUR over the trailing 12 months.
Which sector does the Rocket Pharmaceuticals, Inc. company belong to?
The Rocket Pharmaceuticals, Inc. sector is Healthcare.